Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Early stage breast cancer treatment and prognostic factors

Early stage breast cancer treatment and prognostic factors Developments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Early stage breast cancer treatment and prognostic factors

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/early-stage-breast-cancer-treatment-and-prognostic-factors-JjbMyPxurT
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0328-2
Publisher site
See Article on Publisher Site

Abstract

Developments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Apr 25, 2017

References

  • Predictors of recurrence during years 5–14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)
    Pan, H; Gray, RG; Davies, C
  • First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2–3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
    Tjan-Heijnen, VC; Hellemond, IE; Peer, PG
  • Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)
    Blok, EJ; Velde, CJH; Meershoek-Klein Kranenbarg, EM
  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
    Coleman, R; Gray, R; Powles, T
  • Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
    Hadji, P; Coleman, RE; Wilson, C
  • The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006–04)
    Vliek, SB; Meershoek-Klein Kranenbarg, E; Rossum, AGJ
  • A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) ± estrogen deprivation: NRG oncology/NSABP B‑52. General session 3
    Rimawi, MF; Reena, S; Checchini, M
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    Tolaney, SM; Barry, WT; Dang, CT
  • I-SPY 2: optimising cancer drug development in the 21st century
    Bartsch, R; Azambuja, E
  • DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: results from the neoadjuvant I‑SPY 2 trial for high risk breast cancer
    Wolf, DM; Yau, C; Sanil, A
  • Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ
    Morrow, M; Zee, KJ; Solin, LJ
  • DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population
    Bremer, T; Whitworth, P; Leo, M
  • Population-based validation of the prognostic model ADJUVANT! for early breast cancer
    Olivotto, IA; Bajdik, CD; Ravdin, PM
  • PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
    Wishart, GC; Bajdik, CD; Dicks, E; Provenzano, E
  • Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
    Cardoso, F; Slaets, L; Snoo, F
  • 70-gene signature as an aid to treatment decisions in early-stage breast cancer
    Cardoso, F; van’t Veer, LJ; Bogaerts, J; Slaets, L
  • IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by neoadjuvant chemotherapy
    Bidard, F-C; Michiels, S; Mueller, V